Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, β‐amyloid toxicity, and astrocyte function
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Diet supplementation with ketone bodies (acetoacetate and β‐hydroxybuturate) or medium‐length fatty acids generating ketone bodies has consistently been found to cause modest improvement of mental function in Alzheimer's patients. It was suggested that the therapeutic effect might be more pronounced if treatment was begun at a pre‐clinical stage of the disease instead of well after its manifestation. The pre‐clinical stage is characterized by decade‐long glucose hypometabolism in brain, but ketone body metabolism is intact even initially after disease manifestation. One reason for the impaired glucose metabolism may be early destruction of the noradrenergic brain stem nucleus, locus coeruleus, which stimulates glucose metabolism, at least in astrocytes. These glial cells are essential in Alzheimer pathogenesis. The β‐amyloid peptide Aβ interferes with their cholinergic innervation, which impairs synaptic function because of diminished astrocytic glutamate release. Aβ also reduces glucose metabolism and causes hyperexcitability. Ketone bodies are similarly used against seizures, but the effectively used concentrations are so high that they must interfere with glucose metabolism and de novo synthesis of neurotransmitter glutamate, reducing neuronal glutamatergic signaling. The lower ketone body concentrations used in Alzheimer's disease may owe their effect to support of energy metabolism, but might also inhibit release of gliotransmitter glutamate.imageAlzheimer's disease is a panglial‐neuronal disorder with long‐standing brain hypometabolism, aberrations in both neuronal and astrocytic glucose metabolism, inflammation, hyperexcitability, and dementia. Relatively low doses of β‐hydroxybutyrate can have an ameliorating effect on cognitive function. This could be because of metabolic supplementation or inhibition of Aβ‐induced release of glutamate as gliotransmitter, which is likely to reduce hyperexcitability and inflammation. The therapeutic β‐hydroxybutyrate doses are too low to reduce neuronally released glutamate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Enabling ketone bodies to supply a fraction of needed ATP may partly compensate for the deficiency in glucose metabolism in Alzheimer’s patients.”
BackgroundHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“The authors go on to explain that cerebellar neurons are well supplied with dense networks of fibers originating from brainstem nuclei, above all locus coeruleus, where abnormal tau occurs in remarkably young individuals (Braak and Del Tredici 2011; Braak et al. 2011; Elobeid et al. 2012).”
BackgroundStoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity.
Sibson, N. R., Dhankhar, A., Mason, G. F., Rothman, D. L., Behar, K. L., & Shulman, R. G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.316 · Cited by 897
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss
Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S.-I., Dziewczapolski, G., Nakamura, T., Cao, G., Pratt, A. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306832110 · Cited by 600
Autopsy Samples of Alzheimer's Cortex Show Increased Peroxidation In Vitro
Subbarao, K. V., Richardson, J. S., & Ang, L. C. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb08858.x · Cited by 463
The neuropathology of aminergic nuclei in Alzheimer's disease
Zweig, R. M., Ross, C. A., Hedreen, J. C., Steele, C., Cardillo, J. E., Whitehouse, P. J., Folstein, M. F., & Price, D. L. (1988) · Annals of Neurology · doi:10.1002/ana.410240210 · Cited by 446
AZOULAY-ZOHAR, H., ISRAELSON, A., ABU-HAMAD, S., & SHOSHAN-BARMATZ, V. (2004) · Biochemical Journal · doi:10.1042/bj20031465 · Cited by 408 · cited 2×
“(2015) 134, 7--20 the ADP/ATP carrier (adenine nucleotide translocator), which mediates the exchange of ADP and ATP through the inner mitochondrial membrane (Vyssokikh and Brdiczka 2003; Azoulay-Zohar et al., 2004).”
BackgroundO’Donnell, J., Zeppenfeld, D., McConnell, E., Pena, S., & Nedergaard, M. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0818-x · Cited by 399
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396 · cited 2×
“There is profound neurodegeneration and expression of neurofibrillary tangles in locus coeruleus in Alzheimer’s disease (German et al. 1987; Zweig et al. 1988; Chan-Palay 1991; Busch et al. 1997; Haglund et al. 2006; Grudzien et al. 2007; Takahashi et al. 2015).”
BackgroundAstrocyte Calcium Signaling Transforms Cholinergic Modulation to Cortical Plasticity In Vivo
Takata, N., Mishima, T., Hisatsune, C., Nagai, T., Ebisui, E., Mikoshiba, K., & Hirase, H. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5289-11.2011 · Cited by 382 · cited 3×
“Muscarinic innervation of astrocytes and [Ca]i response requires functional inositol trisphosphate (IP3) receptors (Takata et al. 2011; Chen et al. 2012).”
BackgroundKashiwaya, Y., Bergman, C., Lee, J.-H., Wan, R., King, M. T., Mughal, M. R., Okun, E., Clarke, K., Mattson, M. P., & Veech, R. L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.023 · Cited by 363 · cited 1×
“In a mouse model of Alzheimer’s disease, Kashiwaya et al. (2013) found that a diet where 21.5% of the calories had been switched from carbohydrate to a b-hydroxybutyrate ester improved performance in some conventional memory tests.”
BackgroundInfluentialAbramov, A. Y., Canevari, L., & Duchen, M. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05088.2003 · Cited by 337
Mitochondrial reactive oxygen species and Ca 2+ signaling
Camello-Almaraz, C., Gomez-Pinilla, P. J., Pozo, M. J., & Camello, P. J. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00217.2006 · Cited by 336
Clarke, K., Tchabanenko, K., Pawlosky, R., Carter, E., Todd King, M., Musa-Veloso, K., Ho, M., Roberts, A., Robertson, J., VanItallie, T. B., et al. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.04.008 · Cited by 332
Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307
Astrocytic Control of Biosynthesis and Turnover of the Neurotransmitters Glutamate and GABA
Schousboe, A., Bak, L. K., & Waagepetersen, H. S. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00102 · Cited by 303 · cited 2×
“Moreover, released GABA is to a considerable extent reaccumulated directly into GABAergic neurons (Schousboe et al. 2013; see, however also Patel et al. 2015), whereas almost all released glutamate is taken up by astrocytes (Danbolt 2001; Zhou and Danbolt 2013) and returned to neurons in the…”
BackgroundSelf-citation13 C MRS studies of neuroenergetics and neurotransmitter cycling in humans
Rothman, D. L., De Feyter, H. M., de Graaf, R. A., Mason, G. F., & Behar, K. L. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1772 · Cited by 290
Does Alzheimer's disease begin in the brainstem?
Simic, G., Stanic, G., Mladinov, M., Jovanov‐Milosevic, N., Kostovic, I., & Hof, P. R. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01038.x · Cited by 204 · cited 1×
“Whether or not this is enough to explain the increased incidence of seizures in Alzheimer’s patients (Spencer 2014) remains unknown.”
BackgroundGlycolysis and Glutamate Accumulation into Synaptic Vesicles
Ikemoto, A., Bole, D. G., & Ueda, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211617200 · Cited by 193 · cited 1×
“This could be because the neuronal vesicular glutamate transporter requires glucose for optimum function (Ikemoto et al. 2003).”
BackgroundHypometabolism as a therapeutic target in Alzheimer's disease
Costantini, L. C., Barr, L. J., Vogel, J. L., & Henderson, S. T. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s16 · Cited by 162
Shilling, M., Matt, L., Rubin, E., Visitacion, M. P., Haller, N. A., Grey, S. F., & Woolverton, C. J. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.0303 · Cited by 143 · cited 2×
“Virgin’ (cold-pressed) coconut oil is also a good source of medium-chain fatty acids but in addition contains some higher fatty acids (mainly C-12 and C-14), (Shilling et al. 2013) but no glucose.”
BackgroundPirttimaki, T. M., Codadu, N. K., Awni, A., Pratik, P., Nagel, D. A., Hill, E. J., Dineley, K. T., & Parri, H. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081828 · Cited by 103
Cited by
Cunnane, S. C., Courchesne‐Loyer, A., St‐Pierre, V., Vandenberghe, C., Pierotti, T., Fortier, M., Croteau, E., & Castellano, C. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12999 · Cited by 250
Smilansky, A., Dangoor, L., Nakdimon, I., Ben-Hail, D., Mizrachi, D., & Shoshan-Barmatz, V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691493 · Cited by 143
“VDAC1, HK, Energy Production, Oxidative Stress, and Cell Death—It was demonstrated 35 years ago that brain hypometabolism precedes clinical signs of Alzheimer disease (57, 58), with a significant correlation between hypometabolism and decreased cognitive functioning being noted (4).”
BackgroundLactate deficit in an Alzheimer disease mouse model: the relationship with neuronal damage
Zhang, M., Cheng, X., Dang, R., Zhang, W., Zhang, J., & Yao, Z. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly102 · Cited by 130
Harun-Or-Rashid, M., & Inman, D. M. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1346-7 · Cited by 121
de la Rubia Ortí, J. E., García-Pardo, M. P., Drehmer, E., Sancho Cantus, D., Julián Rochina, M., Aguilar, M. A., & Hu Yang, I. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180184 · Cited by 116
“Therefore, ketone bodies would reduce such hyper-excitability and inflammation, thus improving the course of the illness [17].”
Metadata
- Authors
- Hertz, L., Chen, Y., & Waagepetersen, H. S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2015-04-23
- Volume
- 134
- Issue
- 1
- Pages
- 7-20
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1987746715
- Cited by
- 104
- References
- 26
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.